SVB Leerink Analysts Cut Earnings Estimates for Amedisys, Inc. (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMEDGet Rating) – Investment analysts at SVB Leerink decreased their Q2 2022 earnings per share (EPS) estimates for Amedisys in a research report issued on Friday, April 29th. SVB Leerink analyst W. Mayo now anticipates that the health services provider will post earnings per share of $1.25 for the quarter, down from their prior forecast of $1.38. SVB Leerink currently has a “Market Perform” rating and a $147.00 price target on the stock. SVB Leerink also issued estimates for Amedisys’ Q1 2023 earnings at $1.57 EPS and FY2023 earnings at $6.51 EPS.

AMED has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Amedisys from $230.00 to $210.00 in a report on Friday. Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Amedisys in a report on Friday. Royal Bank of Canada dropped their price objective on shares of Amedisys from $221.00 to $199.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Raymond James dropped their price objective on shares of Amedisys from $200.00 to $180.00 in a report on Friday. Finally, Credit Suisse Group dropped their price objective on shares of Amedisys from $200.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amedisys currently has an average rating of “Buy” and an average target price of $191.06.

AMED stock opened at $127.65 on Monday. The firm has a market capitalization of $4.15 billion, a price-to-earnings ratio of 21.97, a price-to-earnings-growth ratio of 2.26 and a beta of 0.72. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.44. Amedisys has a 12-month low of $122.12 and a 12-month high of $284.59. The firm has a fifty day moving average price of $155.99.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. Amedisys had a net margin of 8.59% and a return on equity of 19.82%. During the same period last year, the business earned $1.54 EPS.

Hedge funds have recently modified their holdings of the company. Quadrature Capital Ltd increased its stake in shares of Amedisys by 375.4% during the 3rd quarter. Quadrature Capital Ltd now owns 33,316 shares of the health services provider’s stock worth $4,967,000 after purchasing an additional 26,308 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in Amedisys by 7.3% in the 4th quarter. New York State Teachers Retirement System now owns 44,390 shares of the health services provider’s stock worth $7,186,000 after buying an additional 3,015 shares during the period. Raymond James & Associates boosted its holdings in Amedisys by 60.9% in the 3rd quarter. Raymond James & Associates now owns 17,101 shares of the health services provider’s stock worth $2,550,000 after buying an additional 6,473 shares during the period. Advisor Partners LLC bought a new position in Amedisys in the 4th quarter worth approximately $215,000. Finally, Riverbridge Partners LLC boosted its holdings in Amedisys by 57.0% in the 4th quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock worth $257,187,000 after buying an additional 576,633 shares during the period. Institutional investors own 92.18% of the company’s stock.

In other news, insider David L. Kemmerly sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $177.31, for a total transaction of $443,275.00. Following the completion of the sale, the insider now owns 16,336 shares in the company, valued at approximately $2,896,536.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.80% of the company’s stock.

Amedisys Company Profile (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.